|Dosage Form||Tablet (oral; 20mg, 30mg, and 40mg)|
|Drug Class||Kinase inhibitors|
|Company||Boehringer Ingelheim Pharmaceuticals|
- For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- For the treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.